MD1003-AMN MD1003 in Adrenomyeloneuropathy

Inclusion Criteria: * ABCD1 gene mutation identified * Elevated plasma VLCFA * Clinical signs of AMN with at least pyramidal signs in the lower limbs and difficulties to walk * EDSS score ≥ 3.5 and ≤ 6.5 * Normal brain MRI or brain MRI showing : * abnormalities that can be observed in AMN patients without cerebral demyelination with a maximum Loes score of 4 * and/or stable (≥6 months) cerebral demyelination without gadolinium enhancement with a Loes score ≤12. * Appropriate steroid replacement if adrenal insufficiency is present * Likely to be able to participate in all scheduled evaluation visits and complete all required study procedures * Signed and dated written informed consent to participate in the study in accordance with local regulations * Affiliated to a Health Insurance Exclusion Criteria: * Brain MRI abnormalities with a Loes score \> 12 or with gadolinium enhancement * Any progressive neurological disease other than AMN * Impossibility to perform the walk tests and the TUG test * Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or any progressive malignancy * Any new medication for AMN including Fampridine initiated less than 1 month prior to inclusion * Contra-indications for MRI procedure such as subjects with paramagnetic materials in the body, such as aneurysm clips, pacemakers, intraocular metal or cochlear implants. * Inclusion in another therapeutic clinical trial for ALD * Not easily contactable by the investigator in case of emergency or not capable to call the investigator